Novo Nordisk
-
healthGlobal Obesity Crisis Widens as Treatment Access Lags in Hardest-Hit Regions
New research reveals obesity rates are accelerating in developing nations while GLP-1 drugs remain concentrated in wealthier countries, highlighting a critical equity gap.
-
healthOzempic Breath: The Unsettling Keto-Like Side Effect Patients Are Reporting
Patients taking GLP-1 drugs report 'fishy' bad breath known as Ozempic breath. Experts discuss dehydration as the likely cause.
-
healthFDA Targets Copycat Weight-Loss Drugs, Limits Bulk Production
The FDA proposes removing Novo Nordisk and Eli Lilly's weight-loss drugs from a compounding list to curb unauthorized bulk production.
-
healthUS Prescription Drug Spending on Track to Exceed $1 Trillion, Fueled by GLP-1s
U.S. drug spending hit $915B in 2025, set to top $1T in 2026, driven by GLP-1 weight-loss drug demand. Eli Lilly and Novo Nordisk dominate the market.
-
healthOral Semaglutide Shows Efficacy in Pediatric Type 2 Diabetes Trial
Phase 3 PIONEER TEENS trial demonstrates oral semaglutide's potential as a first-in-class treatment for adolescents with type 2 diabetes.
-
healthNovo Nordisk Teams Up with OpenAI to Revolutionize Drug Development
Novo Nordisk announces a groundbreaking partnership with OpenAI, leveraging AI to accelerate drug discovery, streamline operations, and enhance patient care.
-
techNovo Nordisk Taps OpenAI for Accelerated Drug Discovery
Novo Nordisk partners with OpenAI to leverage advanced AI, aiming to speed up drug research, improve manufacturing, and bring new treatments for obesity and diabetes to patients faster.
-
techNovo Nordisk Taps OpenAI for AI-Driven Drug Development
Novo Nordisk partners with OpenAI to accelerate drug discovery, enhance manufacturing, and improve efficiency using artificial intelligence in the competitive obesity drug market.